Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P51788

UPID:
CLCN2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P51788; B4DQT9; B4DZ58; E9PBD9; E9PCD2; O14864; Q6IPA9; Q8WU13

BACKGROUND:
The Chloride Channel Protein 2 (CLCN2) functions as a voltage-gated chloride channel, integral for cell volume control, membrane potential equilibrium, and signal transduction. It is involved in aldosterone biosynthesis by causing cell membrane depolarization in the adrenal gland's glomerulosa, which activates voltage-gated Ca2+ channels.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Chloride Channel Protein 2 could open doors to potential therapeutic strategies for treating epilepsy, leukoencephalopathy with ataxia, and familial hyperaldosteronism. Its involvement in these diseases highlights its potential as a target for drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.